Drug Profile
JNJ 55920839
Alternative Names: CNTO-6358; JNJ-55920839Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Class Monoclonal antibodies
- Mechanism of Action Interferon alpha beta receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA (Parenteral)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Belgium (IV, Infusion)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Belgium (SC, Injection)